GATC Biotech to Offer Liquid Biopsy Research Services While Developing Dx With Partners | GenomeWeb

NEW YORK (GenomeWeb) – Building on its experience with cell-free DNA analysis from noninvasive prenatal testing, GATC Biotech of Germany is expanding into oncology with its liquid biopsy technology.

Having offered its GATCLiquid technology through an early access program for several months, the company is launching three liquid biopsy assays as a research service this week. In parallel, the firm is working with a number of collaborators to develop the technology for diagnostic use.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.